Skip to main content
Top
Published in: Familial Cancer 3/2017

01-07-2017 | Original Article

Identification of a rare germline NBN gene mutation by whole exome sequencing in a lung-cancer survivor from a large family with various types of cancer

Authors: Makia J. Marafie, Mohammed Dashti, Fahd Al-Mulla

Published in: Familial Cancer | Issue 3/2017

Login to get access

Abstract

Nijmegen breakage syndrome is an autosomal recessive disorder caused by biallelic mutation in NBN gene. It is characterized by microcephaly, growth retardation, immuno-deficiency and cancer predisposition. The monoallelic carriers of NBN gene are also reported to be at increased risk of developing various types of malignancy. We have investigated an individual with lung cancer from an extended family segregating different types of hereditary cancer over several generations, including lung, breast, ovarian, colon, prostate and renal cancers. By using next generation whole exome sequencing approach, we identified a rare heterozygous frameshift mutation in NBN gene; c.93_94delTG (Ala32HisfsTer4), which is predicted to be pathogenic together with 3 other variants; 2 being in the BRCA1 gene, c.1648A > C (p.Asn550His) and c.536A > G (p.Tyr179Cys), and one in RAD50 gene, c.3539G > A (p.Arg1180Gln). Some of the variants were also found in six out of eight clinically normal relatives, but in different combinations. To our knowledge, this is the first report of NBN gene mutation in an individual with lung cancer in the Arab world. Reporting such findings may aid in variants’ risk classification and clinical decision in the future.
Literature
1.
go back to reference Varon R, Vissinga C, Platzer M, Cerosaletti KM, Chrzanowska KH, Saar K et al (1998) Nibrin, a novel DNA double strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell 93(3):467–476CrossRefPubMed Varon R, Vissinga C, Platzer M, Cerosaletti KM, Chrzanowska KH, Saar K et al (1998) Nibrin, a novel DNA double strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell 93(3):467–476CrossRefPubMed
2.
go back to reference Carney JP, Maser RS, Olivares H, Davis EM, Le Beau M, Yates JR 3rd et al (1998) The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell 93(3):477–486CrossRefPubMed Carney JP, Maser RS, Olivares H, Davis EM, Le Beau M, Yates JR 3rd et al (1998) The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell 93(3):477–486CrossRefPubMed
3.
go back to reference Futaki M, Lui JM (2001) Chromosome breakage syndromes and the BRCA1 genome surveillance complex. Trends Mol Med 7(12):560–565CrossRefPubMed Futaki M, Lui JM (2001) Chromosome breakage syndromes and the BRCA1 genome surveillance complex. Trends Mol Med 7(12):560–565CrossRefPubMed
4.
go back to reference Varon R, Seemanová E, Chrzanowska K, Hnateyko O, Piekutowska-Abramczuk D, Krajewska-Walasek M et al (2000) Clinical ascertainment of Nijmegen breakage syndrome (NBS) and prevalence of the major mutation, 657del5, in three Slav populations. Eur J Hum Genet 8(11):900–902CrossRefPubMed Varon R, Seemanová E, Chrzanowska K, Hnateyko O, Piekutowska-Abramczuk D, Krajewska-Walasek M et al (2000) Clinical ascertainment of Nijmegen breakage syndrome (NBS) and prevalence of the major mutation, 657del5, in three Slav populations. Eur J Hum Genet 8(11):900–902CrossRefPubMed
5.
go back to reference Seemanová E1, Jarolim P, Seeman P, Varon R, Digweed M, Swift M, Sperling K. (2007) Cancer risk of heterozygotes with the NBN founder mutation. JNCI J Natl Cancer Inst 99(24): 1875–1880 Seemanová E1, Jarolim P, Seeman P, Varon R, Digweed M, Swift M, Sperling K. (2007) Cancer risk of heterozygotes with the NBN founder mutation. JNCI J Natl Cancer Inst 99(24): 1875–1880
6.
go back to reference Fang W, Qiu F, Zhang L, Deng J, Zhang H, Yang L, Zhou Y, Lu J (2014) The functional polymorphism of NBS1 p.Glu185Gln is associated with an increased risk of lung cancer in Chinese populations: case-control and a meta-analysis. Mutat Res 770:61–68CrossRefPubMed Fang W, Qiu F, Zhang L, Deng J, Zhang H, Yang L, Zhou Y, Lu J (2014) The functional polymorphism of NBS1 p.Glu185Gln is associated with an increased risk of lung cancer in Chinese populations: case-control and a meta-analysis. Mutat Res 770:61–68CrossRefPubMed
7.
go back to reference Stenson PD, Mort M, Ball EV, Shaw K, Phillips A, Cooper DN (2014) The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Genet 133(1):1–9CrossRefPubMed Stenson PD, Mort M, Ball EV, Shaw K, Phillips A, Cooper DN (2014) The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Genet 133(1):1–9CrossRefPubMed
8.
go back to reference Clarke L, Zheng-Bradley X, Smith R, Kulesha E, Xiao C, Toneva I, Vaughan B, Preuss D, Leinonen R, Shumway M, Sherry S, Flicek P (1000) Genomes Project Consortium (2012) The 1000 Genomes Project: data management and community access. Nat Methods 9(5):459–462CrossRef Clarke L, Zheng-Bradley X, Smith R, Kulesha E, Xiao C, Toneva I, Vaughan B, Preuss D, Leinonen R, Shumway M, Sherry S, Flicek P (1000) Genomes Project Consortium (2012) The 1000 Genomes Project: data management and community access. Nat Methods 9(5):459–462CrossRef
9.
go back to reference Fokkema IF, den Dunnen JT, Taschner PE (2005) LOVD: easy creation of a locus-specific sequence variation database using an “LSDB-in-a-box” approach. Hum Mutat 26(2):63–68CrossRefPubMed Fokkema IF, den Dunnen JT, Taschner PE (2005) LOVD: easy creation of a locus-specific sequence variation database using an “LSDB-in-a-box” approach. Hum Mutat 26(2):63–68CrossRefPubMed
10.
go back to reference Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H et al (2015) COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res 43 (Database issue):D805-811 Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H et al (2015) COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res 43 (Database issue):D805-811
11.
go back to reference Abdel-Rahman MH, Pilarski R, Cebulla CM et al (2011) Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet 48(12):856–859CrossRefPubMed Abdel-Rahman MH, Pilarski R, Cebulla CM et al (2011) Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet 48(12):856–859CrossRefPubMed
12.
go back to reference Helgadottir H, Höiom V, Jönsson G, Tuominen R, Ingvar C, Borg A, Olsson H, Hansson J (2014) High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families. J Med Genet 51(8):545–552CrossRefPubMedPubMedCentral Helgadottir H, Höiom V, Jönsson G, Tuominen R, Ingvar C, Borg A, Olsson H, Hansson J (2014) High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families. J Med Genet 51(8):545–552CrossRefPubMedPubMedCentral
13.
go back to reference Wang Y, McKay JD, Rafnar T et al (2014) Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. NatGenet 46(7):736–741 Wang Y, McKay JD, Rafnar T et al (2014) Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. NatGenet 46(7):736–741
14.
go back to reference Renieri A, Mencarelli MA, Cetta F et al (2014) Oligogenic germline mutations identified in early non-smokers lung adenocarcinoma patients. Lung Cancer 85(2):168–174CrossRefPubMed Renieri A, Mencarelli MA, Cetta F et al (2014) Oligogenic germline mutations identified in early non-smokers lung adenocarcinoma patients. Lung Cancer 85(2):168–174CrossRefPubMed
15.
go back to reference Clamon GH, Bossler AD, Abu Hejleh T, Furqan M (2015) Germline mutations predisposing to non-small cell lung cancer. Fam Cancer 14(3):463–469CrossRefPubMed Clamon GH, Bossler AD, Abu Hejleh T, Furqan M (2015) Germline mutations predisposing to non-small cell lung cancer. Fam Cancer 14(3):463–469CrossRefPubMed
16.
go back to reference Tomoshige K, Matsumoto K, Tsuchiya T, Oikawa M, Miyazaki T, Yamasaki N, Mishima H, Kinoshita A, Kubo T, Fukushima K, Yoshiura KI, Nagayasu T (2015) Germline mutations causing familial lung cancer. J Hum Genet 60(10):597–603CrossRefPubMed Tomoshige K, Matsumoto K, Tsuchiya T, Oikawa M, Miyazaki T, Yamasaki N, Mishima H, Kinoshita A, Kubo T, Fukushima K, Yoshiura KI, Nagayasu T (2015) Germline mutations causing familial lung cancer. J Hum Genet 60(10):597–603CrossRefPubMed
17.
go back to reference El-Harith el-HA1, Abdel-Hadi MS, Steinmann D, Dork T (2002). BRCA1 and BRCA2 mutations in breast cancer patients from Saudi Arabia. Saudi Med J. 23(6):700–704 El-Harith el-HA1, Abdel-Hadi MS, Steinmann D, Dork T (2002). BRCA1 and BRCA2 mutations in breast cancer patients from Saudi Arabia. Saudi Med J. 23(6):700–704
18.
go back to reference Spurdle AB, Lakhani SR, Healey S, Parry S, Da Silva LM, Brinkworth R, Hopper JL, Brown MA, Babikyan D, Chenevix-Trench G et al (2008) Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis–a report from the kConFab Investigators. J Clin Oncol 26(10):1657–1663CrossRefPubMed Spurdle AB, Lakhani SR, Healey S, Parry S, Da Silva LM, Brinkworth R, Hopper JL, Brown MA, Babikyan D, Chenevix-Trench G et al (2008) Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis–a report from the kConFab Investigators. J Clin Oncol 26(10):1657–1663CrossRefPubMed
19.
go back to reference Lindor NM1, Guidugli L, Wang X, Vallée MP, Monteiro AN, Tavtigian S, Goldgar DE, Couch FJ (2012) A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS) Hum Mutat. 33(1):8–21 Lindor NM1, Guidugli L, Wang X, Vallée MP, Monteiro AN, Tavtigian S, Goldgar DE, Couch FJ (2012) A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS) Hum Mutat. 33(1):8–21
20.
go back to reference Park SL, Bastani D, Goldstein BY, Chang SC, Cozen W, Cai L et al (2010) Associations between NBS1 polymorphisms, haplotypes and smoking-related cancers. Carcinogenesis 31(7):1264–1271CrossRefPubMedPubMedCentral Park SL, Bastani D, Goldstein BY, Chang SC, Cozen W, Cai L et al (2010) Associations between NBS1 polymorphisms, haplotypes and smoking-related cancers. Carcinogenesis 31(7):1264–1271CrossRefPubMedPubMedCentral
Metadata
Title
Identification of a rare germline NBN gene mutation by whole exome sequencing in a lung-cancer survivor from a large family with various types of cancer
Authors
Makia J. Marafie
Mohammed Dashti
Fahd Al-Mulla
Publication date
01-07-2017
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 3/2017
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-016-9954-9

Other articles of this Issue 3/2017

Familial Cancer 3/2017 Go to the issue

Original Article

Gastric tumours in FAP

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine